The study was conducted to assess the prognostic value of different variables on the outcome of a Type first tympanoplasty alone and combined with intact canal wall mastoidectomy in Chronic Otitis Media (CSOM) in pediatric patients.

BackgroundIndividuals with difficult-to-treat migraine, including resistant migraine (ResM) and refractory migraine (RefM), might experience treatment delays, undergo unnecessary diagnostic tests and receive misdiagnoses, which might influence treatment outcomes. For this reason, we hypothesized that individuals with ResM and RefM might report more diagnostic tests and misdiagnoses in their medical history compared with those with non-resistant/non-refractory migraine (NRNRM).MethodsThis analysis used baseline, cross-sectional data from the REFINE study, a multicenter, prospective observational study conducted in 15 European tertiary headache centers. Adults with episodic or chronic migraine were classified into RefM, ResM, or NRNRM groups. Baseline data were analyzed to assess the frequency of previous diagnostic tests and misdiagnoses.ResultsOverall, 689 participants were included with a median age of 46 years (interquartile range 36-53); 570 participants (82.7%) were female; 355 (51.5%) had NRNRM, 261 (37.9%) ResM, and 73 (10.9%) RefM. Referring to diagnostic tests, 335 participants (48.7%) had one and 237 (34.4%) multiple brain magnetic resonance imaging scans. ResM and RefM participants underwent more diagnostic tests than NRNRM. Overall, 193 participants (28.0%) had at least one prior headache misdiagnosis, most commonly cervical spine disorders and sinusitis; misdiagnoses were more frequent in NRNRM and ResM than in RefM (31.1%, 28.5%, and 15.1%, respectively; p = 0.025). Misdiagnosis rates were not influenced by age, sex, disease duration, or comorbidities.ConclusionsDiagnostic tests use and misdiagnoses are highly prevalent in all the three groups of individuals with ResM, RefM, and NRNRM with some differences across the three groups that may depend on multiple factors. Our findings emphasize a need for better diagnostic accuracy and care pathway across the entire spectrum of migraine, to avoid unnecessary diagnostic tests and misdiagnoses.

Depemokimab is a monoclonal antibody that targets interleukin-5 with enhanced binding affinity and an extended terminal elimination half‑life of 6-8 weeks. The unique pharmacodynamic features of depemokimab enable sustained suppression of type 2 inflammation with twice‑yearly subcutaneous dosing. This narrative review provides details of depemokimab's molecular profile, pharmacokinetics, and pharmacodynamics and results regarding the clinical efficacy and safety of depemokimab from recently published Phase 3 clinical trials for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP). In 528 severe adult CRSwNP patients (ANCHOR‑1/‑2 trials), depemokimab achieved Δ total endoscopic nasal polyp score by -0.70 (p < .001) and Δ nasal obstruction verbal response scale by -0.24 (p = .003) at week 52, compared to placebo. Twice‑yearly 100 mg depemokimab provides durable eosinophil suppression and with a safety profile comparable to placebo in Phase 3 trials for CRSwNP. Future work should refine biomarkers and assess comparative cost‑effectiveness and long‑term adherence, safety, and effectiveness.

Functional endoscopic sinus surgery (FESS) is a widely used procedure for chronic sinusitis. Although it is generally considered a safe procedure, serious ophthalmic complications might occur. In this report, we discuss the results of Foster augmented full tendon vertical muscle transposition (VRT) with and without resection for two cases presented with iatrogenic complete medial rectus transection following FESS.

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a prevalent yet inadequately understood condition characterized by benign lesions originating from inflamed nasal sinuses. It impacts patients by inducing nasal obstruction, inflammation, and recurrent symptoms. The pathophysiological mechanisms underlying nasal polyposis are not fully elucidated, which constrains the efficacy of current therapeutic interventions such as intranasal corticosteroids (INCSs), functional endoscopic sinus surgery (FESS), and biologics, particularly in severe, treatment-resistant, or recurrent cases. Recent research indicates that calcium (Ca[2+]) channels, notably with the use of blockers like Verapamil, may provide therapeutic benefits by addressing these challenges, demonstrating promising outcomes without significant adverse effects. Nonetheless, the molecular mechanisms involving Ca[2+]-dependent signaling pathways in CRSwNP remain insufficiently characterized, with a paucity of studies examining their dysregulation and contribution to disease pathology. Consequently, identifying critical components involved in disruptions of Ca[2+] signaling is of paramount importance.